# Paratus Sciences Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paratus-sciences

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.paratussciences.com
- Total disclosed funding: $21M
- Latest round: Series A (Feb 27, 2023)
- Investors on record: 6

## About

Founded in 2021 and based in New York, US, Paratus Sciences Corporation uses research on bat biology to enhance human health and health security. As of March 2023, Amir Nashat serves as the CEO of the company. In February 2023, Paratus Sciences Corporation raised USD 100 million in Series A funding from Arch Venture Partners, Clavystbio, EcoR1 Capital, Leaps by Bayer, Polaris Partners, and Alexandria Venture Investments.

The company delivers a therapeutic discovery platform that focuses on identifying and developing new medicines for a wide range of disorders by unlocking the bat genome. The firm’s biology approach includes deep sequencing, bioinformatics and machine learning, protein structure prediction, stem cells, protein-protein interaction mapping, bat antibody libraries, comparative genetics, and animal models.

## Funding rounds

- Series A, Feb 27, 2023, $21M — ARCH Venture Partners, Polaris Partners, Alexandria Venture Investments, EcoR1 Capital, Leaps by Bayer, ClavystBio

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A
- ClavystBio (https://capitalatlas.ai/funds/clavystbio) — Series A